Search Results
Search for other papers by Claudio Ricci in
Google Scholar
PubMed
‘Vita-Salute’ San Raffaele University, Milan, Italy
Search for other papers by Stefano Partelli in
Google Scholar
PubMed
Search for other papers by Carlo Ingaldi in
Google Scholar
PubMed
‘Vita-Salute’ San Raffaele University, Milan, Italy
Search for other papers by Valentina Andreasi in
Google Scholar
PubMed
Search for other papers by Davide Campana in
Google Scholar
PubMed
‘Vita-Salute’ San Raffaele University, Milan, Italy
Search for other papers by Francesca Muffatti in
Google Scholar
PubMed
Search for other papers by Laura Alberici in
Google Scholar
PubMed
‘Vita-Salute’ San Raffaele University, Milan, Italy
Search for other papers by Cecilia Giorgi in
Google Scholar
PubMed
Search for other papers by Riccardo Casadei in
Google Scholar
PubMed
‘Vita-Salute’ San Raffaele University, Milan, Italy
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
resulting long overall survival (OS), even in the presence of recurrent disease, makes it difficult to design multi-arm randomized trials due to the long observation period needed. Some authors advocate ( Kulke et al. 2011 ) the use of progression
Departments of Cardiac Surgery , Cardiovascular Research, Obstetrics and Gynecology, Medical University of Vienna and Comprehensive Cancer Center, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Search for other papers by Seyedhossein Aharinejad in
Google Scholar
PubMed
Departments of Cardiac Surgery , Cardiovascular Research, Obstetrics and Gynecology, Medical University of Vienna and Comprehensive Cancer Center, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Search for other papers by Mohamed Salama in
Google Scholar
PubMed
Search for other papers by Patrick Paulus in
Google Scholar
PubMed
Search for other papers by Karin Zins in
Google Scholar
PubMed
Search for other papers by Andreas Berger in
Google Scholar
PubMed
Search for other papers by Christian F Singer in
Google Scholar
PubMed
women who had developed breast cancer during 1992 and 1998, and the results were published in 2008. We prospectively evaluated serum CSF1 concentrations, clinical, and histo-pathological parameters and 5-year overall survival (OS) in 1260 women with
Department of Clinical Sciences, Lund University, Lund, Sweden
Department of General and Endocrine Surgery, OLV Clinic Aalst, Aalst, Belgium
Search for other papers by Klaas Van Den Heede in
Google Scholar
PubMed
Department of Endocrine Surgery, Hammersmith Hospital, London, UK
Search for other papers by Swathikan Chidambaram in
Google Scholar
PubMed
Department of Head and Skin, University Hospital Ghent, Ghent, Belgium
Department of General Surgery, AZ Damiaan, Ostend, Belgium
Search for other papers by Sam Van Slycke in
Google Scholar
PubMed
Global Health Institute, University of Antwerp, Wilrijk, Belgium
Search for other papers by Nele Brusselaers in
Google Scholar
PubMed
Department of Oncology and Pathology, Lund University, Lund, Sweden
Search for other papers by Carl Fredrik Warfvinge in
Google Scholar
PubMed
Department of Surgery, Ystad Hospital, Ystad, Sweden
Search for other papers by Håkan Ohlsson in
Google Scholar
PubMed
Search for other papers by Rita Gustafsson in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund, Sweden
Search for other papers by Erik Nordenström in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund, Sweden
Search for other papers by Martin Almquist in
Google Scholar
PubMed
siNETs and improved treatment options seem to result in a favorable overall survival, even in an advanced, metastatic setting at diagnosis ( Yao et al. 2008 , Rinke et al. 2009 , Wyld et al. 2021 ). Differences in terminology (historical), lack of
Search for other papers by T P Links in
Google Scholar
PubMed
Search for other papers by K M van Tol in
Google Scholar
PubMed
Search for other papers by P L Jager in
Google Scholar
PubMed
Search for other papers by J Th M Plukker in
Google Scholar
PubMed
Search for other papers by D A Piers in
Google Scholar
PubMed
Search for other papers by H M Boezen in
Google Scholar
PubMed
Search for other papers by R P F Dullaart in
Google Scholar
PubMed
Search for other papers by E G E de Vries in
Google Scholar
PubMed
Search for other papers by W J Sluiter in
Google Scholar
PubMed
specific and overall, decrease with advancing age at diagnosis and should be reported separately for several age categories within the sample. By analogy, visual presentation as, for example, by Kaplan–Meier plots should include survival curves for each age
Search for other papers by Anela Blažević in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Gaston J H Franssen in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Search for other papers by Marie-Louise F van Velthuysen in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
(data not shown). Effect of mesenteric fibrosis on survival During a median follow-up time of 62.3 months (IQR 32.9–103.4), 208 patients died. Kaplan–Meier analysis demonstrated that patients with MF had a significantly shorter overall survival
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
Search for other papers by Yu-Li Chen in
Google Scholar
PubMed
Search for other papers by Cheng-Yang Chou in
Google Scholar
PubMed
Search for other papers by Ming-Cheng Chang in
Google Scholar
PubMed
Search for other papers by Han-Wei Lin in
Google Scholar
PubMed
Search for other papers by Ching-Ting Huang in
Google Scholar
PubMed
Search for other papers by Shu-Feng Hsieh in
Google Scholar
PubMed
Search for other papers by Chi-An Chen in
Google Scholar
PubMed
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
Search for other papers by Wen-Fang Cheng in
Google Scholar
PubMed
Introduction Ovarian carcinoma is the most lethal gynecologic malignancy ( Jemal et al . 2011 ). The standard treatment for this disease is debulking surgery followed by platinum-based chemotherapy; however, the overall survival (OS) rate is around
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Carmine Valenza in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Francesco Multinu in
Google Scholar
PubMed
Search for other papers by Lavinia Benini in
Google Scholar
PubMed
Search for other papers by Michele Borghesani in
Google Scholar
PubMed
Search for other papers by Laura Algeri in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Eleonora Pisa in
Google Scholar
PubMed
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Chiara Alessandra Cella in
Google Scholar
PubMed
Search for other papers by Silvestro Carinelli in
Google Scholar
PubMed
Search for other papers by Simone Bruni in
Google Scholar
PubMed
Search for other papers by Gabriella Schivardi in
Google Scholar
PubMed
Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
Search for other papers by Giuseppe Curigliano in
Google Scholar
PubMed
Search for other papers by Vanna Zanagnolo in
Google Scholar
PubMed
Division of Gynecologic Surgery, European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy
Search for other papers by Giovanni Aletti in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Search for other papers by Nicoletta Colombo in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
, respectively ( Gadducci et al. 2017 ). The prognosis is extremely poor and depends on the disease extension: 5-year overall survival (OS) rate ranges from 30 to 60% in patients with early stage disease to 0–15% in those with metastatic disease ( Tempfer et
Search for other papers by Thierry Petit in
Google Scholar
PubMed
Search for other papers by Patrick Dufour in
Google Scholar
PubMed
Search for other papers by Ian Tannock in
Google Scholar
PubMed
with metastatic breast cancer. These drugs increase the rate of tumour response and enhance progression-free survival from 6 to 10 months, but none of the randomised studies has shown an improvement in overall survival ( Bonneterre et al . 2001
Search for other papers by Zaid Al-Qurayshi in
Google Scholar
PubMed
Department of Head and Neck Surgical Oncology, NCI, Cairo University, Cairo, Egypt
Search for other papers by Mohamed A Shama in
Google Scholar
PubMed
Search for other papers by Gregory W Randolph in
Google Scholar
PubMed
Search for other papers by Emad Kandil in
Google Scholar
PubMed
://www.facs.org/quality-programs/cancer/ncdb ) Accessed October 15, 2015). The primary study objective is to assess the impact of tumor size and MEE on the overall survival in patients with DTC. The secondary study objective is to assess the survival benefit of total thyroidectomy vs lobectomy and
Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Search for other papers by David L Chan in
Google Scholar
PubMed
Search for other papers by Victor Rodriguez-Freixinos in
Google Scholar
PubMed
Search for other papers by Hans Chung in
Google Scholar
PubMed
Search for other papers by Julie Hallet in
Google Scholar
PubMed
Search for other papers by Calvin Law in
Google Scholar
PubMed
Search for other papers by Chirag Patel in
Google Scholar
PubMed
Search for other papers by Laurent Milot in
Google Scholar
PubMed
Search for other papers by John Hudson in
Google Scholar
PubMed
Search for other papers by Hanbo Chen in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
rate of combined everolimus and radiation as measured by RECIST v1.1, per-lesion local control, progression-free survival and overall survival. Patients were clinically assessed following 14 and 28 days of initial everolimus, weekly during concurrent